InvestorsHub Logo
Followers 0
Posts 21
Boards Moderated 0
Alias Born 08/07/2019

Re: None

Monday, 10/05/2020 3:48:04 PM

Monday, October 05, 2020 3:48:04 PM

Post# of 66
H.C. Wainwright raises VYNE Therapeutics target
Oct. 05, 2020 3:24 PM ETVYNE Therapeutics Inc. (VYNE)By: Shweta Agarwal, SA News Editor1 Comment

VYNE Therapeutics (NASDAQ:VYNE) is up 10% after H.C. Wainwright reiterated its Buy rating and boosted its price target on ZILXI's (minocycline) entry to U.S. pharmaceutical market.
The firm raised its price target to $3.50 from $3, implying an approximately 97% upside.
Analyst Oren Livnat says: Amzeeq growth is on track, and Zilxi is about to launch with "coverage out of the gate and dermatologists eager for better rosacea treatment."

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VYNE News